Tradename | Company | Number | Date | Products |
---|---|---|---|---|
AGGRENOX | Boehringer Ingelheim | N-020884 DISCN | 1999-11-22 | 1 products, RLD |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
PERSANTINE | Boehringer Ingelheim | N-012836 DISCN | 1986-12-22 | 3 products, RLD |
IV PERSANTINE | Boehringer Ingelheim | N-019817 DISCN | 1990-12-13 | 1 products, RLD |
Brand Name | Status | Last Update |
---|---|---|
aggrenox | New Drug Application | 2016-08-06 |
aspirin and dipyridamole | ANDA | 2023-12-26 |
aspirin and dipyridamole extended release | ANDA | 2019-01-18 |
aspirin and extended - release dipyridamole capsules, 25 mg / 200 mg | ANDA | 2025-01-14 |
aspirin and extended-release dipyridamole | ANDA | 2025-04-23 |
aspirin-dipyridamole | ANDA | 2023-05-15 |
asprin and extended-release dipyridamole | ANDA | 2021-05-31 |
dipyridamole | ANDA | 2025-01-08 |
dipyridamole dipyridamole | ANDA | 2018-12-14 |
Code | Description |
---|---|
G9531 | Patient has documentation of ventricular shunt, brain tumor, multisystem trauma, or is currently taking an antiplatelet medication including: abciximab, anagrelide, cangrelor, cilostazol, clopidogrel, dipyridamole, eptifibatide, prasugrel, ticlopidine, ticagrelor, tirofiban, or vorapaxar |
J1245 | Injection, dipyridamole, per 10 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 14 | — | — | 1 | — | 15 |
Stroke | D020521 | EFO_0000712 | I63.9 | — | — | 2 | 2 | — | 4 |
Ischemic stroke | D000083242 | — | — | — | — | — | 1 | — | 1 |
Coronary artery disease | D003324 | — | I25.1 | — | — | — | 1 | — | 1 |
Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | — | 1 | — | 1 |
Arteriosclerosis | D001161 | EFO_0009086 | I70 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Covid-19 | D000086382 | — | U07.1 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Peripheral arterial disease | D058729 | EFO_0004265 | — | — | — | — | — | 1 | 1 |
Peripheral vascular diseases | D016491 | EFO_0003875 | I73.9 | — | — | — | — | 1 | 1 |
Drug common name | Dipyridamole |
INN | dipyridamole |
Description | Dipyridamole is a pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots. It has a role as an adenosine phosphodiesterase inhibitor, an EC 3.5.4.4 (adenosine deaminase) inhibitor, a platelet aggregation inhibitor and a vasodilator agent. It is a member of piperidines, a pyrimidopyrimidine, a tertiary amino compound and a tetrol. |
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | OCCN(CCO)c1nc(N2CCCCC2)c2nc(N(CCO)CCO)nc(N3CCCCC3)c2n1 |
PDB | — |
CAS-ID | 58-32-2 |
RxCUI | — |
ChEMBL ID | CHEMBL932 |
ChEBI ID | 4653 |
PubChem CID | 3108 |
DrugBank | DB00975 |
UNII ID | 64ALC7F90C (ChemIDplus, GSRS) |